Time to fight: targeting the circadian clock molecular machinery in cancer therapy.
Journal
Drug discovery today
ISSN: 1878-5832
Titre abrégé: Drug Discov Today
Pays: England
ID NLM: 9604391
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
received:
22
09
2020
revised:
23
11
2020
accepted:
22
01
2021
pubmed:
8
2
2021
medline:
19
1
2022
entrez:
7
2
2021
Statut:
ppublish
Résumé
The circadian clock regulates a wide range of molecular pathways and biological processes. The expression of clock genes is often altered in cancer, fostering tumor initiation and progression. Inhibition and activation of core circadian clock genes, as well as treatments that restore circadian rhythmicity, have been successful in counteracting tumor growth in different experimental models. Here, we provide an up-to-date overview of studies that show the therapeutic effects of targeting the clock molecular machinery in cancer, both genetically and pharmacologically. We also highlight future areas for progress that offer a promising path towards innovative anticancer strategies. Substantial limitations in the current understanding of the complex interplay between the circadian clock and cancer in vivo need to be addressed in order to allow clock-targeting therapies in cancer.
Identifiants
pubmed: 33549826
pii: S1359-6446(21)00053-2
doi: 10.1016/j.drudis.2021.01.023
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1164-1184Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.